Aurora Biopharma Receives NYSE American Delisting Notice and Files Appeal

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

JACKSONVILLE, Fla., April 4, 2025 – AIM ImmunoTech (NYSE American: AIM) today announced that it has received a notice of delisting from the NYSE American LLC (NYSE American) due to the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2024.

The notice of delisting was issued by the NYSE American on April 3, 2025, and the Company has been given 10 days to appeal the delisting. AIM ImmunoTech has appealed the delisting and is working to resolve the issue as quickly as possible.

The Company is currently working to complete its financial statements and file its Form 10-K as soon as possible. AIM ImmunoTech is committed to providing accurate and timely financial information to its shareholders and the investing public.

The Company's common stock will be suspended from trading on the NYSE American effective April 14, 2025, pending the outcome of the appeal. If the appeal is denied, the Company's common stock will be delisted from the NYSE American.

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of cancer-toxin therapies. The Company's lead product candidate, Amplimmune, is a novel, proprietary, and patented technology that is designed to enhance the body's immune response to cancer. Amplimmune is being evaluated in multiple clinical trials, including a Phase 2 trial for the treatment of non-small cell lung cancer.

For more information, please visit www.aimimmune-tech.com.

Contact: Thomas A. Oakley, Chief Financial Officer (904) 392-9827 toakley@aimimmune-tech.com